|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oskar Gold, Vetter’s Senior VP, Key Account Management and Marketing/Corporate Communications, offers his insights on aseptic manufacturing and why careful thought and consideration of different criteria must be applied.
|
|
|
Sebby Borriello, Vice President & Chief Commercial Officer, speaks about the challenges and trends surrounding development of therapies for neurological diseases.
|
|
|
Ed Price, President and CEO of PCI Synthesis, reflects on the trends fostering the CDMO industry consolidation and the positive impact it augurs in addressing sponsors’ needs to enter the clinic more quickly and safely.
|
|
|
Sy Pretorius, MD, Senior VP, Medical & Scientific Services at PAREXEL, discusses the new Patient Innovation Center and how it is helping to improve the patient experience, enhance study recruitment and retention, reduce costs, and deliver better data.
|
|
|
Dr. Martine Dehlinger-Kremer, Vice President, Pediatric Development at Synteract, reviews current and significant challenges in pediatric clinical research, advancement of regulations surrounding them, and where the industry is headed.
|
|
|
Bob Ward, Chairman and CEO at Eloxx Pharmaceuticals, discusses nonsense mutations and how his company’s goal is to bring safe and effective therapies to children and adults suffering from genetic diseases as quickly as possible.
|
|
|
Simon Edwards, President, CDMO Sales & Marketing at Cambrex, discusses the biggest trends in the small molecule outsourcing market.
|
|
|
|
|
|
|
|
|

BD is a reliable partner that can provide expertise in highly specific fields to support your drug throughout its lifecycle, from development to launch and beyond. The company is committed to building partnerships with pharmaceutical and biotechnology companies and developing product solutions that meet their needs by leveraging our innovative technologies, extensive global manufacturing, and advanced technical, scientific, medical, and regulatory expertise. Click here for more.
|
|
|
|
|
|
 |
|
Appili Therapeutics Inc. recently announced it has signed an agreement with FUJIFILM Toyama Chemical Co., Ltd. to acquire and develop the novel……
|
|
 |
|
On November 20 at the 6th Annual Personalized Nanomedicine Symposium, researchers working with Excision BioTherapeutics, a gene therapy company focusing on curing viral infectious diseases, delivered two oral presentations to review the multiple years of…
|
|
 |
|
Catalent recently announced it had entered into a long-term commercial supply agreement with BeiGene, Ltd., a biopharmaceutical company focused on developing….
|
|
|
|
|
Upcoming eNewsletter Features:
December 4 – Capsules
December 11 – Controlled Release
|
|
|
|
|
|
|
|